---
companies:
- category: unknown
  confidence: medium
  context: Welcome everyone to the AI and Business Podcast. I'm Matthew Demelo, Editorial
    Director here at E
  name: Business Podcast
  position: 31
- category: unknown
  confidence: medium
  context: come everyone to the AI and Business Podcast. I'm Matthew Demelo, Editorial
    Director here at Emerge AI Research. T
  name: Matthew Demelo
  position: 53
- category: unknown
  confidence: medium
  context: the AI and Business Podcast. I'm Matthew Demelo, Editorial Director here
    at Emerge AI Research. Today's guest is Dami
  name: Editorial Director
  position: 69
- category: unknown
  confidence: medium
  context: t. I'm Matthew Demelo, Editorial Director here at Emerge AI Research. Today's
    guest is Damian Nero, Head of Data Scien
  name: Emerge AI Research
  position: 96
- category: unknown
  confidence: medium
  context: ctor here at Emerge AI Research. Today's guest is Damian Nero, Head of
    Data Science in US Medical at Takeda Pha
  name: Damian Nero
  position: 133
- category: unknown
  confidence: medium
  context: I Research. Today's guest is Damian Nero, Head of Data Science in US Medical
    at Takeda Pharmaceuticals. With ove
  name: Data Science
  position: 154
- category: unknown
  confidence: medium
  context: y's guest is Damian Nero, Head of Data Science in US Medical at Takeda
    Pharmaceuticals. With over 15 years of
  name: US Medical
  position: 170
- category: unknown
  confidence: medium
  context: amian Nero, Head of Data Science in US Medical at Takeda Pharmaceuticals.
    With over 15 years of experience applying AI mac
  name: Takeda Pharmaceuticals
  position: 184
- category: unknown
  confidence: medium
  context: ioned all the other stuff that's floating around. So I think that you were
    seeing sort of an acceleratio
  name: So I
  position: 3020
- category: unknown
  confidence: medium
  context: en the two and the lack of comfort and sometimes. But I, I completely understand
    the motivations and ther
  name: But I
  position: 7225
- category: unknown
  confidence: medium
  context: ata in a way we haven't been able to in the past. With AI being able to
    screen through this, we're able to
  name: With AI
  position: 7621
- category: unknown
  confidence: medium
  context: trust in pharmaceutical brands, especially in the United States right now,
    and a lot of, and a lot of populations
  name: United States
  position: 9277
- category: unknown
  confidence: medium
  context: ng on and off of plans constantly, even since the Affordable Care Act was
    put in place. That's still commonplace. Add t
  name: Affordable Care Act
  position: 10330
- category: unknown
  confidence: medium
  context: ation that we can start to piece things together. Now AI does help with
    this in terms of smoothing things
  name: Now AI
  position: 11693
- category: unknown
  confidence: medium
  context: at it's being used as sort of background support. And I think I spoke to
    this last time in the last talk
  name: And I
  position: 15659
- category: tech
  confidence: high
  context: d then get enough buy-in that will give us enough runway to do the more
    creative and inventive things that
  name: Runway
  position: 18814
- category: unknown
  confidence: medium
  context: ms of AI policy from the United States to the EU. The EU much more organized,
    but also having a way higher
  name: The EU
  position: 19324
- category: unknown
  confidence: medium
  context: aling challenges that you were describing before. So Damien, really, really
    fascinating stuff across targetin
  name: So Damien
  position: 23161
date: 2025-05-07 06:00:00 +0000
duration: 27
has_transcript: false
insights:
- actionable: false
  confidence: medium
  extracted: AI and drug development lies in proactive systems. Takeda
  text: the future of AI and drug development lies in proactive systems. Takeda is
    working toward models that flag risks, draft submissions, and support decisions
    before challenges arise, shifting clinical workflows from reactive to predictive.
  type: prediction
layout: episode
llm_enhanced: true
original_url: https://traffic.libsyn.com/secure/techemergence/Business_-_5.7.25_-_Damion_Nero.mp3?dest-id=151434
processing_date: 2025-10-05 19:40:37 +0000
quotes:
- impact_reason: A critical warning about the risk of AI hallucination or over-extrapolation
    when trained on noisy, incomplete data sets.
  relevance_score: 10
  source: llm_enhanced
  text: AI tends to have a capacity to, I mean, for lack of a better term, exaggerate.
    In a sense that it will take a bit of information and turn it into something that
    is totally not the case.
  topic: technology
- impact_reason: 'Provides a counter-intuitive regulatory insight: the US regulatory
    environment (outside of strict drug approval) can be looser than in the EU or
    Asia regarding new technologies like AI integration.'
  relevance_score: 10
  source: llm_enhanced
  text: Something that isn't commonly talked about is that the US actually has some
    of the looser regulations. FDA is pretty stringent about the drug approval process.
    You go to the EU, you go to Asia, forget it. The standards are much, much higher
    there and there are a lot of requirements that they have.
  topic: regulation
- impact_reason: 'Exposes the ''black box'' problem amplified by outsourcing: reliance
    on proprietary, unexplained third-party algorithms severely limits internal trust
    and explainability, hindering adoption for critical tasks.'
  relevance_score: 10
  source: llm_enhanced
  text: We're not really in a position right now where there isn't A, enough trust
    even internally to do that and B, we could actually explain it well. Because also
    keep in mind, we're not building a lot of this in-house. A lot of this is being
    outsourced to third parties. And for many of them, this is a black box type of
    situation where they'll build it for us. Sure, they won't tell us how they did
    it. They'll say, it's a proprietary algorithm that we own and then that's it.
  topic: technology/strategy
- impact_reason: 'Compares the global regulatory landscape: EU is organized with high
    privacy/risk standards (like GDPR/AI Act), while the US approach is fragmented.'
  relevance_score: 10
  source: llm_enhanced
  text: The EU much more organized, but also having a way higher standard when it
    comes to personal privacy, the risk categories for different kinds of AI systems
    than the United States, which is a far more piecemeal system.
  topic: regulation
- impact_reason: 'Presents the future vision for clinical trials: extreme decentralization/virtualization,
    minimizing patient-HCP interaction to reduce aversion and cost.'
  relevance_score: 10
  source: llm_enhanced
  text: Beyond that, as we get more and more into decentralized trials and really
    just virtualizing a lot of that process as well, where really the interactions
    with HCPs are kept to maybe once during the entire trial, ideally or maybe never.
    That is really, I think, the gold standard that we're moving towards as well to
    get, move past any sort of patient aversion, reduce our costs as well...
  topic: adoption/technology
- impact_reason: 'Provides a concrete example of proactive AI application: moving
    clinical workflows from reacting to problems to predicting and preventing them
    (flagging risks, drafting submissions).'
  relevance_score: 10
  source: llm_enhanced
  text: Takeda is working toward models that flag risks, draft submissions, and support
    decisions before challenges arise, shifting clinical workflows from reactive to
    predictive.
  topic: technology/strategy
- impact_reason: Highlights the major industry shift towards decentralized clinical
    trials (DCTs), a key trend accelerated by technology and patient preference post-COVID.
  relevance_score: 9
  source: llm_enhanced
  text: We're kind of shifting more towards what we refer to as a decentralized model
    where you don't necessarily have everything being run through in other facilities.
    There's a lot of remote and basically electronic interaction with the patients,
    everything from doing consent forms to checkups, things like that, to telehealth...
  topic: adoption
- impact_reason: A crucial insight into the current, conservative deployment of AI
    in pharma—focused on process improvement rather than direct clinical decision-making.
  relevance_score: 9
  source: llm_enhanced
  text: AI's role today remains largely operational, working behind the scenes to
    drive efficiencies rather than directly influencing trial outcomes.
  topic: strategy
- impact_reason: A powerful metric demonstrating the speed and objectivity AI brings
    to image analysis, overcoming human bias.
  relevance_score: 9
  source: llm_enhanced
  text: Computer vision, which is basically just using AI and visualization technology
    to actually assess imaging data, has taken huge strides and they can screen through
    100,000 images in three minutes and they make comparisons and assess them in ways
    that are completely objective.
  topic: technology
- impact_reason: Clearly identifies historical site data fragmentation as the primary
    systemic hurdle in leveraging AI for strategic trial planning.
  relevance_score: 9
  source: llm_enhanced
  text: The bottleneck, at least even to get to the patients, is historical site data.
  topic: strategy
- impact_reason: Emphasizes the non-negotiable need for expert human data curation
    to mitigate risks associated with flawed input data.
  relevance_score: 9
  source: llm_enhanced
  text: We need to be mindful of anything that is based off of incomplete or inconsistent
    data. And that really still requires a good human element, you know, in terms
    of data scientists, programmers, others to really curate and make sure what's
    being fed in kind of gets rid of some of that or at least adjusts for some of
    that before you start modeling off of it...
  topic: strategy
- impact_reason: Provides a direct analysis of how the pandemic severely eroded patient
    trust in both pharmaceutical and healthcare institutions, impacting trial recruitment.
  relevance_score: 9
  source: llm_enhanced
  text: The lockdowns killed their trust in pharma. And then the incidents of COVID
    killed their trust in healthcare facilities and keeping them safe. So the combination
    of the two has been a persistent thing within all of our patient populations...
  topic: adoption
- impact_reason: Highlights the critical necessity of human oversight (data scientists,
    programmers) to clean and curate data before feeding it into AI models, addressing
    the inherent risk of poor input data quality.
  relevance_score: 9
  source: llm_enhanced
  text: And so we need to be mindful of anything that is based off of incomplete or
    inconsistent data. And that really still requires a good human element, you know,
    in terms of data scientists, programmers, others to really curate and make sure
    what's being fed in kind of gets rid of some of that or at least adjusts for some
    of that before you start modeling off of it, before you start feeding it into
    the AI.
  topic: technology/strategy
- impact_reason: 'A critical observation on data infrastructure: HIPAA regulations,
    while important, are primarily structured around payment facilitation rather than
    comprehensive healthcare data sharing, creating systemic gaps.'
  relevance_score: 9
  source: llm_enhanced
  text: These gaps in data that they foster because especially for HIPAA, they're
    more meant to facilitate payment rather than healthcare.
  topic: regulation/technology
- impact_reason: Confirms that AI hallucinations are a persistent, long-term challenge,
    particularly in high-stakes fields like pharmaceuticals, impacting reliability.
  relevance_score: 9
  source: llm_enhanced
  text: The hallucinations factor that you had mentioned and that you're telling our
    audience is going to be with us for quite a while, especially where we see it
    in pharmaceutical spaces.
  topic: technology
- impact_reason: 'Pinpoints the current barrier to advanced AI use: using AI to generate
    primary outcome reports invites intense scrutiny regarding methodology and explainability.'
  relevance_score: 9
  source: llm_enhanced
  text: Because if you're using it to drive outcomes, if you're using this to create
    materials that you're going to say, okay, this is a report that is actually showing
    what's happening with these patients and we use AI to generate the results, there
    are a lot of hard questions about that and how this was actually done.
  topic: technology/regulation
- impact_reason: 'A strong strategic recommendation: serious, long-term AI integration
    requires building and maintaining internal expertise, rather than relying solely
    on outsourcing.'
  relevance_score: 9
  source: llm_enhanced
  text: At some point, if you really want to be serious about this, we're going to
    have to build and more so keep a team to do this.
  topic: strategy/business
- impact_reason: Argues that the outsourcing model prevents true mastery and trust
    in AI capabilities, contrasting the long-term investment required (years) versus
    short-term ROI pressures.
  relevance_score: 9
  source: llm_enhanced
  text: As long as you keep up with that model [outsourcing], long-term, you can never
    really do this because you never get able to trust the outsourced groups. And
    without an internal team working a long time, and yes, they're going to burn cash,
    then that always going to be productive because everything that they do is longer.
    You take some years to build these things out, not months.
  topic: strategy
- impact_reason: 'Outlines the pragmatic strategy for driving AI adoption: focus initially
    on ''low-hanging fruit'' that demonstrates clear operational cost savings (ROI)
    to build internal momentum.'
  relevance_score: 9
  source: llm_enhanced
  text: I'm not saying it's hopeless because it is a paradigm shift happening. And
    as we get more wins and more use cases, that's why we're taking smaller steps.
    We're really focused on low-hanging fruit. Again, things that they show in operational
    efficiencies like, look, we're saving you money here.
  topic: strategy/adoption
- impact_reason: Predicts that AI growth will be fastest in the drug discovery phase
    because it is 'least outward-facing,' meaning it faces fewer immediate regulatory
    and trust hurdles.
  relevance_score: 9
  source: llm_enhanced
  text: How far is the low-hanging fruit going to get us in that time? No, I think
    it'll get us pretty far. I think probably the space where you'll see this grow
    the fastest is in the discovery space because that is the least outward-facing
    part of what we do.
  topic: adoption/technology
- impact_reason: Identifies drug discovery simulation and candidate generation as
    the area offering the highest near-term value with relatively low investment risk.
  relevance_score: 9
  source: llm_enhanced
  text: Really increasing the number of potential candidates more rapidly, doing virtual
    simulations, having data that we already have to test some of these scenarios
    out. I think that can provide massive value with very little investment.
  topic: technology/investment
- impact_reason: 'A clear summary point on AI''s immediate impact: driving the shift
    towards decentralized trials via remote engagement tools.'
  relevance_score: 9
  source: llm_enhanced
  text: AI is accelerating decentralization in clinical trials with technologies like
    chatbots and telehealth, streamlining remote patient engagement and reducing the
    burden of in-person participation.
  topic: adoption/technology
- impact_reason: 'Summarizes the primary barriers to advanced AI use: data fragmentation
    and internal trust issues, emphasizing the need for transparency to move beyond
    administrative support.'
  relevance_score: 9
  source: llm_enhanced
  text: Scaling AI in clinical settings faces major headwinds from fragmented historical
    site data to internal trust gaps. Damien emphasizes the importance of transparent
    systems and internal alignment to make AI more than just a back office tool.
  topic: technology/strategy
- impact_reason: Defines AI's essential role in managing the influx of diverse data
    streams generated by decentralized trials and improving patient engagement.
  relevance_score: 8
  source: llm_enhanced
  text: AI is critical there because we're going to be getting in a lot of data and
    a lot of things coming from different sources. We need to be able to process and
    track that also allowing for easier ways to interact with patients, chatbots,
    for example...
  topic: technology
- impact_reason: 'Identifies the primary constraint for advanced AI adoption in rare
    disease trials: insufficient data volume.'
  relevance_score: 8
  source: llm_enhanced
  text: It's a challenge because we just don't have the volume of patients to really
    do that [AI implementation] in terms of actually, you know, trials around developing
    drugs for rare disease...
  topic: technology
- impact_reason: Pinpoints oncology as the immediate, high-impact area for AI deployment
    due to superior data availability.
  relevance_score: 8
  source: llm_enhanced
  text: I see this having a larger impact is probably in areas like oncology, where
    we definitely have the numbers, just holistically, that even if you talk about
    specific tumor types... you have plenty of information to train off of.
  topic: adoption
- impact_reason: A candid, human observation on the emotional bias in subjective clinical
    assessments, highlighting why objective AI analysis is necessary.
  relevance_score: 8
  source: llm_enhanced
  text: They don't come in always with the, you know, the most precise diagnosis because
    they like to be hopeful. They have to be hopeful because these patients are facing
    the reality of death. And so many times their assessments in what's reflected
    is not realistic. It's it's a sense that it knows not based on any objective measures
    is the unobjective opinion.
  topic: business
- impact_reason: Directly links AI implementation to achieving objective clinical
    assessment, a major goal in precision medicine.
  relevance_score: 8
  source: llm_enhanced
  text: I think having AI in that space has definitely improved and allowed for us
    to have real objective assessment because we're getting direct access to the data
    in a way we haven't been able to in the past.
  topic: technology
- impact_reason: Explains the root cause of data inconsistency in the US healthcare
    system (insurance flux, government programs), which impacts AI training.
  relevance_score: 8
  source: llm_enhanced
  text: Our healthcare system in the US is very fractured. You have people that are
    switching on and off of plans constantly... A lot of these healthcare programs,
    the government sponsors still give you sort of sporadic data.
  topic: regulation
- impact_reason: 'Identifies a major systemic issue post-COVID: eroded patient trust
    in both pharmaceutical companies and healthcare facilities, impacting patient
    participation and compliance.'
  relevance_score: 8
  source: llm_enhanced
  text: But again, this has been an issue for years and frankly, it's been sort of
    a systemic issue since COVID because we never really recovered from that in terms
    of patients having the same level of trust. The lockdowns killed their trust in
    pharma. And then the incidents of COVID killed their trust in healthcare facilities
    and keeping them safe.
  topic: adoption/business
- impact_reason: Illustrates the significant internal organizational friction required
    to deploy new AI solutions, needing consensus among clinical, legal, and regulatory
    stakeholders.
  relevance_score: 8
  source: llm_enhanced
  text: The regulatory guys, they're like, no way in the world that we ever going
    to get this past them. So you're going to have to describe this idea. So you get
    the clinical people, regulatory people, and the legal people in the same room.
    Getting them to agree on anything around this is a challenge in itself.
  topic: strategy/regulation
- impact_reason: 'Explains why cutting-edge, complex AI projects are often the first
    casualties during cost-cutting: lack of immediate, understandable value to leadership/investors.'
  relevance_score: 8
  source: llm_enhanced
  text: The thing that nobody understands and doesn't really seem to be generating
    any value right now, there's always on the chopping block for them.
  topic: business/investment
- impact_reason: 'The core pitch for future AI investment: trade short-term operational
    savings for resources needed to develop revenue-generating, pipeline-pushing capabilities
    later.'
  relevance_score: 8
  source: llm_enhanced
  text: If you give us a little bit of leeway, we can actually make you more money
    down the line if you just give us resources to build out and do this more.
  topic: investment/strategy
- impact_reason: 'Describes the ''first-mover advantage'' dynamic in adopting transformative,
    high-risk technologies: success triggers rapid industry-wide adoption, while failure
    causes stagnation.'
  relevance_score: 8
  source: llm_enhanced
  text: It's waiting for that moment to come, I think more than anything else because
    it's actually someone who's got to be the first. Now if they fail, well, then
    it gets set back a while. But I have hope and I think it's more likely that they
    will succeed and succeed in a big way in which case everybody will run to catch
    up.
  topic: investment/strategy
- impact_reason: Provides a balanced view on AI integration, acknowledging that human
    oversight remains crucial while efficiency drives automation.
  relevance_score: 7
  source: llm_enhanced
  text: This is still a very human-driven process, don't get me wrong. And there's
    still a lot of people that's involved in this necessary, probably in perpetuity,
    but there's going to be parts of this that are more and more automated out of
    necessity and frankly just out of the sake of efficiency...
  topic: strategy
- impact_reason: Articulates the core business imperative driving the adoption of
    AI and efficiency measures in drug development.
  relevance_score: 7
  source: llm_enhanced
  text: We need to really move a little bit faster to meet our patients' need more
    quickly and to broaden the number of, you know, drugs that we're putting out on
    the market in order to meet the new challenges in healthcare that keep coming
    at us.
  topic: business
- impact_reason: Highlights the vulnerability of specialized data science teams in
    pharma to corporate restructuring and political/economic pressures, hindering
    long-term AI capability development.
  relevance_score: 7
  source: llm_enhanced
  text: The layoffs have been targeted specifically in data scientists by our politicians
    and in addition to manufacturing a lot of other things. But those teams, I've
    seen completely wiped out where you'll have an entire office shut down.
  topic: business/strategy
- impact_reason: The core task requires analyzing the provided text for key insights,
    predictions, and technical explanations related to the specified topics (especially
    crypto/Web3). Without the text, no analysis can occur.
  relevance_score: 1
  source: llm_enhanced
  text: I cannot generate the quotes because the transcript content was not provided.
  topic: N/A
source: Unknown Source
summary: "## Podcast Episode Summary: Scaling AI for Clinical Trials - with Damion\
  \ Nero of Takeda\n\nThis 26-minute episode of the AI and Business Podcast features\
  \ Damion Nero, Head of Data Science in US Medical at Takeda Pharmaceuticals, discussing\
  \ the transformative role of AI and digital technologies in modernizing clinical\
  \ trials and drug development. The core narrative focuses on the shift toward decentralized\
  \ trial models, the systemic challenges hindering widespread AI adoption, and the\
  \ strategic path forward for realizing tangible ROI.\n\n---\n\n1. **Focus Area**:\
  \ **AI in Pharmaceutical Clinical Trials and Drug Development.** Key themes include\
  \ the acceleration of decentralized clinical trials (DCTs), leveraging real-world\
  \ data (RWD), precision medicine applications, and overcoming operational and regulatory\
  \ hurdles for scaling AI solutions.\n\n2. **Key Technical Insights**:\n    * **Decentralized\
  \ Trial Acceleration:** AI is critical for processing the influx of data from remote\
  \ patient interactions (telehealth, electronic consent, chatbots for symptom tracking)\
  \ inherent in decentralized trial models.\n    * **Computer Vision in Diagnostics:**\
  \ AI, particularly computer vision, is making significant strides in objective tumor\
  \ diagnosis by rapidly screening and assessing imaging data, overcoming human subjectivity\
  \ driven by emotional factors.\n    * **Data Integrity and Hallucination Risk:**\
  \ AI models trained on fractured, inconsistent historical site data risk \"exaggerating\"\
  \ effects or generating misleading insights (hallucinations), necessitating strong\
  \ human curation by data scientists.\n\n3. **Market/Investment Angle**:\n    * **Focus\
  \ on High-Volume Areas:** AI impact is currently greatest in areas with large patient\
  \ populations (e.g., oncology) where data volume can adequately train models, rather\
  \ than in rare disease trials where data scarcity is a major constraint.\n    *\
  \ **ROI Driven by Operational Efficiency:** Initial investment justification relies\
  \ on \"low-hanging fruit\"—demonstrating clear operational efficiencies and cost\
  \ savings behind the scenes to secure leadership buy-in for more complex, outcome-driving\
  \ AI projects.\n    * **Competitive Catalyst:** Significant industry-wide adoption\
  \ is anticipated once a competitor achieves a major, verifiable success with advanced\
  \ AI, forcing others to follow suit to satisfy investor demands.\n\n4. **Notable\
  \ Companies/People**:\n    * **Damion Nero (Takeda):** Guest expert providing an\
  \ insider's view on AI deployment, data challenges, and internal alignment within\
  \ a major pharmaceutical company.\n    * **Takeda Pharmaceuticals:** The context\
  \ for the discussion, highlighting current strategies in data science and clinical\
  \ operations.\n    * **Metable:** Sponsor of the special series on AI and clinical\
  \ workflow.\n\n5. **Regulatory/Policy Discussion**:\n    * **Global Regulatory Stringency:**\
  \ The US FDA is considered relatively \"looser\" compared to regulatory bodies in\
  \ the EU and Asia, which impose significantly higher standards, complicating the\
  \ deployment of novel AI-driven trial materials globally.\n    * **Internal Alignment\
  \ Challenge:** Achieving consensus among clinical, regulatory, and legal teams regarding\
  \ the use of AI-generated results is a major internal hurdle, often leading companies\
  \ to keep AI applications strictly in administrative or background support roles.\n\
  \    * **Black Box Concerns:** Reliance on third-party vendors for AI development\
  \ often results in proprietary \"black box\" algorithms, which prevents internal\
  \ teams from fully understanding or explaining the methodology to regulators.\n\n\
  6. **Future Implications**:\n    * **Discovery Space Growth:** AI will likely see\
  \ the fastest growth in the drug discovery phase (virtual simulations, candidate\
  \ generation) as it is the least outward-facing and requires less immediate regulatory\
  \ approval.\n    * **Virtualization as Gold Standard:** The long-term goal is to\
  \ move toward fully virtualized trials, minimizing in-person HCP interactions to\
  \ reduce patient aversion and operational costs.\n    * **Shift to Proactive Systems:**\
  \ The ultimate trajectory involves moving beyond operational efficiencies to proactive\
  \ systems that flag risks, draft submissions, and support decisions before issues\
  \ arise, transforming clinical workflows from reactive to predictive.\n\n7. **Target\
  \ Audience**: **Pharmaceutical Professionals, Clinical Operations Leaders, Data\
  \ Science Executives in Healthcare, and Investors focused on HealthTech/Biotech.**\
  \ Professionals needing a realistic, candid assessment of AI scaling challenges\
  \ in highly regulated environments will find this most valuable."
tags:
- artificial-intelligence
- investment
title: Scaling AI for Clinical Trials - with Damion Nero of Takeda
topics:
- keywords:
  - ai
  - machine learning
  - deep learning
  - neural networks
  - llm
  - large language model
  mentions: 57
  prominence: 1.0
  topic: artificial intelligence
- keywords:
  - investment
  - funding
  - valuation
  - ipo
  - acquisition
  mentions: 1
  prominence: 0.1
  topic: investment
---

<!-- Episode automatically generated from analysis data -->
<!-- Processing completed: 2025-10-05 19:40:37 UTC -->
